Cocaine Use Disorder (CUD): Current Clinical Perspectives
- PMID: 36093428
- PMCID: PMC9451050
- DOI: 10.2147/SAR.S337338
Cocaine Use Disorder (CUD): Current Clinical Perspectives
Abstract
Cocaine use disorder (CUD) is a devastating disorder, impacting both individuals and society. Individuals with CUD face many barriers in accessing treatment for CUD, and most individuals with CUD never receive treatment. In this review, we provide an overview of CUD, including risk factors for CUD, common co-occurring disorders, acute and chronic effects of cocaine use, and currently available pharmacological and behavioral treatments. There are no FDA-approved pharmacological treatments for CUD. Future studies with larger sample sizes and testing treatment combinations are warranted. However, individuals with CUD and co-occurring disorders (eg, a mood or anxiety disorder) may benefit from medication treatments. There are behavioral interventions that have demonstrated efficacy in treating CUD - contingency management (CM) and cognitive-behavioral therapy for substance use disorders (CBT-SUD) in particular - however many barriers remain in delivering these treatments to patients. Following the discussion of current treatments, we highlight some promising emerging treatments, as well as offer a framework that can be used in building a treatment plan for individuals with CUD.
Keywords: behavioral interventions; cocaine; cocaine use disorder; pharmacotherapy; treatment.
© 2022 Schwartz et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures

Similar articles
-
Cognitive dysfunction in individuals with cocaine use disorder: Potential moderating factors and pharmacological treatments.Exp Clin Psychopharmacol. 2019 Jun;27(3):203-214. doi: 10.1037/pha0000245. Epub 2018 Dec 17. Exp Clin Psychopharmacol. 2019. PMID: 30556731 Free PMC article. Review.
-
Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.Front Psychiatry. 2024 Feb 29;15:1230699. doi: 10.3389/fpsyt.2024.1230699. eCollection 2024. Front Psychiatry. 2024. PMID: 38487570 Free PMC article.
-
Hypothalamic-pituitary-adrenal axis activity in post-traumatic stress disorder and cocaine use disorder.Stress. 2020 Nov;23(6):638-650. doi: 10.1080/10253890.2020.1803824. Epub 2020 Aug 24. Stress. 2020. PMID: 32835581 Review.
-
Pharmacotherapy for the Treatment of Cannabis Use Disorder: A Systematic Review [Internet].Washington (DC): Department of Veterans Affairs (US); 2019 Feb. Washington (DC): Department of Veterans Affairs (US); 2019 Feb. PMID: 32227801 Free Books & Documents. Review.
-
GABAergic polygenic risk for cocaine use disorder is negatively correlated with precuneus activity during cognitive control in African American individuals.Addict Behav. 2021 Mar;114:106695. doi: 10.1016/j.addbeh.2020.106695. Epub 2020 Oct 10. Addict Behav. 2021. PMID: 33153773 Free PMC article.
Cited by
-
In vitro and in vivo stability of a highly efficient long-acting cocaine hydrolase.Sci Rep. 2024 May 13;14(1):10952. doi: 10.1038/s41598-024-61646-7. Sci Rep. 2024. PMID: 38740850 Free PMC article.
-
Neuroscience education for people living with addiction.J Psychiatry Neurosci. 2024 Dec 17;49(6):E440-E443. doi: 10.1503/jpn.240153. Print 2024 Nov-Dec. J Psychiatry Neurosci. 2024. PMID: 39689938 Free PMC article. No abstract available.
-
Cocaine self-administration attenuates brain glucose metabolism and functional connectivity in rats.PLoS One. 2025 Jun 6;20(6):e0324522. doi: 10.1371/journal.pone.0324522. eCollection 2025. PLoS One. 2025. PMID: 40478894 Free PMC article.
-
COT-TT vaccine attenuates induction and expression of cocaine-induced behavioral sensitization in rats: a dose-response study.Front Psychiatry. 2025 Jun 3;16:1548585. doi: 10.3389/fpsyt.2025.1548585. eCollection 2025. Front Psychiatry. 2025. PMID: 40530054 Free PMC article.
-
Cocaine Self-Administration Differentially Modulates the Content of Cholesterol, Progesterone, and Testosterone in the Brain and Plasma of Male Rats.Neuroendocrinology. 2025;115(6-7):483-492. doi: 10.1159/000544983. Epub 2025 Mar 3. Neuroendocrinology. 2025. PMID: 40031873
References
-
- Administration SAaMHS. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. HHS Publication No. SMA 18-5068, NSDUH Series H-53. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2018.
-
- SAMHSA. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health; National Findings. SAMHSA; 2014. - PubMed
Publication types
LinkOut - more resources
Full Text Sources